<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>萨托里乌斯表示，基于对未来市场发展的评估，公司预计其可服务市场在中期内将以每年约 7% 至 9% 的速度增长。在此背景下，萨托里乌斯为 2027 年及以后的时期设定了新的中期目标。管理层预计，公司将持续超越其可服务市场，每年增长约 100 至 200 个基点，从而实现集团层面以固定货币计算的有机销售收入增长率为每年 8% 至 11%。此外，集团层面的基础 EBITDA 利润率预计每年将增长约 50 至 75 个基点。</p>
<p>公司旨在通过加强在过程强化、一次性技术和细胞分析等关键应用中的领导地位来巩固其核心业务。萨托里乌斯计划进一步发展一些新兴业务，包括先进疗法解决方案、先进细胞模型、过程分析技术以及分析表征和质量控制平台。</p>
<p>在最后一次收盘时，萨托里乌斯的股票交易价格为 209.00 欧元，下跌 0.33%。</p>
<p>欲获取更多健康新闻，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

<p>萨托里乌斯（Sartorius）设定了新的中期财务目标，预计其可服务市场将以每年 7-9% 的速度增长。该公司旨在超越这一增长，目标是每年实现 100-200 个基点的增长，预计从 2027 年起，公司的有机销售收入年增长率将达到 8-11%。此外，萨托里乌斯预计其基础 EBITDA 利润率将每年增加 50-75 个基点。公司将重点加强核心业务领域，并开发先进疗法解决方案和分析技术等新兴领域。萨托里乌斯的股票最近交易价格为 209.00 欧元，下跌 0.33%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Sartorius said, based on its assessment of future market development, the company expects its addressable markets to grow at a rate of approximately 7 to 9 percent per year over the medium term. Against this backdrop, Sartorius introduced a new medium-term ambition for the period from 2027 onwards. Management expects the company to consistently outgrow its addressable markets by around 100 to 200 basis points per year leading to an organic sales revenue growth in constant currencies of 8 to 11 percent per year at group level. Also, underlying EBITDA margin at group level is supposed to grow by approximately 50 to 75 basis points per year.</p>
<div class="lb-trans"><p>萨托里乌斯表示，基于对未来市场发展的评估，公司预计其可服务市场在中期内将以每年约 7% 至 9% 的速度增长。在此背景下，萨托里乌斯为 2027 年及以后的时期设定了新的中期目标。管理层预计，公司将持续超越其可服务市场，每年增长约 100 至 200 个基点，从而实现集团层面以固定货币计算的有机销售收入增长率为每年 8% 至 11%。此外，集团层面的基础 EBITDA 利润率预计每年将增长约 50 至 75 个基点。</p>
</div><p>The company aims to strengthen its core business by reinforcing its leadership positions in mission-critical applications in process intensification, single-use technologies and cell analytics. Sartorius plans to further develop select emerging businesses, including advanced therapy solutions, advanced cell models, process analytical technologies and analytical characterization and quality control platforms.</p>
<div class="lb-trans"><p>公司旨在通过加强在过程强化、一次性技术和细胞分析等关键应用中的领导地位来巩固其核心业务。萨托里乌斯计划进一步发展一些新兴业务，包括先进疗法解决方案、先进细胞模型、过程分析技术以及分析表征和质量控制平台。</p>
</div><p>At last close, Sartorius shares were trading at 209.00 euros, down 0.33%.</p>
<div class="lb-trans"><p>在最后一次收盘时，萨托里乌斯的股票交易价格为 209.00 欧元，下跌 0.33%。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲获取更多健康新闻，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Sartorius 发布了新的中期财务目标